Skip to content
Tenfell
Awarded contract
Published 23 Apr 2021

NHS Framework for the Midlands and East, Branded Medicines - Tranche B

NHS England · London

Key facts

Awarded
25 Jan 2021
Contract starts
01 Mar 2021
Contract ends
28 Feb 2023
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 37 suppliers

SupplierValue
Accord-UK Ltd—
Takeda UK Limited—
CST Pharma Ltd—
Dr Reddy's Laboratories (UK) Ltd—
Janssen-Cilag Ltd—
Pfizer Ltd—
Teva UK Ltd—
Bayer plc—
Amgen Ltd—
Napp Pharmaceuticals—
Sandoz Ltd—
Thornton & Ross Ltd—
AstraZeneca—
Biogen—
Celltrion Healthcare United Kingdom Limited—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Merck Serono Limited—
Merck Sharpe & Dohme (UK) Limited—
Mylan—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Organon Pharmaceuticals UK Ltd—
Roche Products Ltd—
Sobi (Swedish Orphan Biovitrum Ltd)—
UCB Pharma Ltd—
Day Lewis Medical Ltd—
Ferring Pharmaceuticals Limited—
LEO Pharma Ltd—
Bristol Myers Squibb—
ROVI Biotech Ltd—
UL Global Pharma—
Techdow Pharma England Ltd—
Aventis Pharma Ltd—
Daiichi Sankyo UK Ltd—

Description

NHS Framework for the Midlands and East, Branded Medicines - Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.